title: Distribution of podoplanin-positive tumor vessels predicts disease-specific survival of node-positive breast cancer patients treated with anthracyclines and/or taxanes.
abstract: We analyzed survival of 102 invasive ductal, node positive breast cancer patients, treated with surgery and adjuvant chemotherapy (anthracyclines and/or taxanes) with relation to: (a) well-known clinicopathological parameters, (b) MIB-1 labeling index (LI), (c) the distribution of podoplanin-positive vessels (DPV), expression of: (d) basal markers, and (e) fascin. Lower progression risk was found for patients with tumors characterized by (i) pN1 + pN2, (ii) MIB-1LI ≤ 28%, (iii) lack of lymphatic vessels or high tumor DPV than for patients with pN3, MIB-1LI > 28%, low DPV, respectively. Cox multivariate analysis revealed that both pN3 and low DPV were negative prognostic indicators.
authors.affiliation: Department of Applied Radiobiology,1 Department of Tumor Pathology,2 Department of Head and Neck Cancers,3 Department of Surgical Oncology,4 Maria Skłodowska-Curie Memorial Institute, Centre of Oncology, Cracow Branch, Krakow, Poland.
authors.forename: Joanna A
authors.initials: JA
authors.lastname: Niemiec
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Adamczyk
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Ambicka
authors.forename: Anna
authors.initials: A
authors.lastname: Mucha-Małecka
authors.forename: Wojciech M
authors.initials: WM
authors.lastname: Wysocki
authors.forename: Janusz
authors.initials: J
authors.lastname: Ryś
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D018952:Antigens, CD34 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002352:Carrier Proteins / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008207:Lymphatic Metastasis; D042601:Lymphatic Vessels / Q000378:metabolism* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008840:Microfilament Proteins / Q000378:metabolism; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D043823:Taxoids / Q000627:therapeutic use*; D055815:Young Adult; D000098853:Podoplanin
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D019394:Ki-67 Antigen; D008562:Membrane Glycoproteins; D008840:Microfilament Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; C117468:PDPN protein, human; D000098853:Podoplanin; C020324:fascin; C508053:ERBB2 protein, human